据天眼查APP显示，瑞康医药集团股份有限公司成立于2004年09月21日，注册资本150471.0471万人民 币。（数据宝） 近日该股表现 瑞康医药盘中涨停，已连收3个涨停板，截至9:35，该股报4.26元，换手率5.37%，成交量7333.23万股， 成交金额3.03亿元，涨停板封单金额为2.95亿元。连续涨停期间，该股累计上涨33.13%，累计换手率为 37.66%。最新A股总市值达64.10亿元，A股流通市值58.17亿元。 证券时报·数据宝统计，两融数据来看，该股最新（12月4日）两融余额为2.32亿元，其中，融资余额 2.31亿元，较前一个交易日增加2936.54万元，环比增长14.53%，近3日累计增加1317.02万元，环比增长 6.03%。 龙虎榜数据显示，该股因连续三个交易日内，涨幅偏离值累计达20%、日涨幅偏离值达7%上榜龙虎榜1 次，买卖居前营业部中，机构净卖出2188.28万元，营业部席位合计净卖出1077.88万元。 | 日期 | 当日涨跌幅（%） | 换手率（%） | 主力资金净流入（万元） | | --- | --- | --- | --- | | 2025.12.04 | 9 ...

Group 1 - The company's stock price experienced an abnormal fluctuation, with a cumulative closing price increase exceeding 20% over two consecutive trading days on December 3 and December 4, 2025 [2] - The company conducted a self-examination and verified with major stakeholders, confirming that there were no corrections or supplements needed for previously disclosed information [3] - The company did not find any recent media reports that could have significantly impacted its stock price [4] Group 2 - The company's operational situation remains normal, with no significant changes in its business environment [5] - There are no undisclosed major matters related to the company that should have been disclosed according to regulations [7] - The company confirmed that there were no violations of fair information disclosure regulations [6]

证券日报网讯12月4日晚间，瑞康医药（002589）发布公告称，公司股票交易价格于2025年12月3日、 2025年12月4日连续两个交易日内收盘价格涨幅偏离值累计超过20%，根据《深圳证券交易所交易规 则》的有关规定，属于股票交易异常波动。 ...

Core Viewpoint - The company announced that its stock experienced an abnormal fluctuation, with a cumulative price increase exceeding 20% over two consecutive trading days on December 3 and 4, 2025 [1] Summary by Relevant Sections - **Stock Performance** The company's stock price increased by over 20% in total during the specified trading days, indicating significant market activity [1] - **Self-Examination and Verification** The company conducted a self-examination and confirmed that there was no need to correct or supplement previously disclosed information. No undisclosed significant information was found in media reports [1] - **Operational Status** The company's production and operations are reported to be normal, with no significant matters that should have been disclosed but were not [1] - **Insider Trading** During the period of abnormal fluctuation, the controlling shareholders did not engage in buying or selling the company's stock, and there were no violations of fair information disclosure regulations [1] - **Investor Advisory** The company advised investors to make rational investment decisions and to be aware of potential risks [1]

瑞康医药集团股份有限公司 股票交易异常波动公告 证券代码：002589 证券简称：瑞康医药 公告编号：2025-054 一、股票交易异常波动的情况介绍 瑞康医药集团股份有限公司（股票简称：瑞康医药，股票代码：002589，以 下简称"公司"）股票交易价格于 2025 年 12 月 3 日、2025 年 12 月 4 日连续两个 交易日内收盘价格涨幅偏离值累计超过 20%，根据《深圳证券交易所交易规则》 的有关规定，属于股票交易异常波动。 二、公司关注、核实情况说明 针对公司股票交易异常波动的情况，公司进行了自查，并向公司控股股东、 实际控制人及持股 5%以上股东，全体董事及高级管理人员就相关事项进行了核 实，现就有关情况说明如下： 3、近期公司生产经营情况正常，公司经营情况及内外部经营环境未发生重 大变化。 4、公司、控股股东和实际控制人不存在关于公司的应披露而未披露的重大 事项，或处于筹划阶段的重大事项。 5、在公司股票异常波动期间，公司控股股东、实际控制人及其一致行动人 不存在买卖公司股票的情况。 6、公司不存在违反公平信息披露规定的情形。 三、是否存在应披露而未披露信息的说明 公司董事会确认，公司目前没 ...

Core Viewpoint - 瑞康医药's stock experienced a significant increase, reaching the daily limit with a turnover rate of 24.58% and a transaction volume of 1.282 billion yuan, indicating strong market interest and volatility [2]. Trading Activity - The stock's price rose by 10.10%, leading to its inclusion on the Shenzhen Stock Exchange's watchlist for significant price deviation [2]. - Institutional investors net sold 22.4579 million yuan, while total net selling from brokerage seats amounted to 6.3127 million yuan [2]. - The top five brokerage seats accounted for a total transaction volume of 208 million yuan, with buying amounting to 89.6331 million yuan and selling at 118 million yuan, resulting in a net sell of 28.7706 million yuan [2]. Fund Flow - The stock saw a net outflow of 88.0528 million yuan from major funds, with large orders contributing to a net outflow of 53.1893 million yuan and big orders at 34.8636 million yuan [2]. - Over the past five days, the stock experienced a net inflow of 53.4196 million yuan [2]. Margin Trading - As of December 3, the margin trading balance for 瑞康医药 was 203 million yuan, with a financing balance of 202 million yuan and a securities lending balance of 484.7 thousand yuan [2]. - In the last five days, the financing balance decreased by 20.2736 million yuan, representing a decline of 9.12%, while the securities lending balance increased by 55.3 thousand yuan, showing a rise of 12.89% [2].

据天眼查APP显示，瑞康医药集团股份有限公司成立于2004年09月21日，注册资本150471.0471万人民 币。（数据宝） 数据宝统计，截至10:06，瑞康医药成交额10.68亿元，创2022年12月19日以来新高。最新股价上涨 8.52%，换手率20.54%。上一交易日该股全天成交额为3.62亿元。 ...

每经AI快讯，12月4日，医药流通板块短线拉升，瑞康医药涨停，药易购、海王生物、国科恒泰、合富 中国、开开实业等跟涨。 （文章来源：每日经济新闻） ...

Core Viewpoint - The pharmaceutical distribution sector experienced a short-term surge, with significant gains in various companies, indicating a positive market sentiment in this industry [1] Group 1: Company Performance - Ruikang Pharmaceutical reached its daily limit increase, reflecting strong investor interest and confidence in its stock [1] - Other companies such as Yaoyigou, Haiwang Biological, Guoke Hengtai, Hefuchina, and Kaikai Industrial also saw increases, suggesting a broader rally in the pharmaceutical distribution sector [1]

Market Overview - The market experienced fluctuations with the ChiNext Index dropping over 1% and a total transaction volume of 1.68 trillion [1] - The superhard materials sector showed resilience, with Huanghe Xuanfeng hitting the daily limit and Sifangda rising over 10% [1] - The coal sector saw collective gains, with companies like Dayou Energy and Antai Group reaching the daily limit [1] - The flu prevention concept was active, with Yisheng Pharmaceutical hitting the daily limit and Yue Wannianqing rising over 10% [1] - Overall, more stocks declined than rose, with over 3,800 stocks in the Shanghai, Shenzhen, and Beijing markets in the red [1] Hot Topics Cultivated Diamonds - The cultivated diamond sector surged, with Huanghe Xuanfeng and Guoji Heavy Industry hitting the daily limit, and Sifangda increasing by 15% [4] - The demand for diamond as a heat dissipation material is expected to grow significantly due to advancements in semiconductor technology [5] - The diamond heat dissipation market is projected to expand from $0.37 million in 2025 to $15.2 billion by 2030, indicating explosive growth [6] Coal Sector - The coal sector performed well, with Antai Group achieving two consecutive daily limits and companies like Huitian Thermal Power and New Dazhou A also hitting the daily limit [7] - A cold wave affecting central and eastern China has led to significant temperature drops, boosting energy procurement demand [7] - Analysts expect coal prices to maintain upward momentum due to stricter safety regulations and increased demand during the winter heating season [8] Pharmaceutical Sector - The pharmaceutical sector was active again, with Haiwang Biological achieving six consecutive daily limits and companies like Ruikang Pharmaceutical and Yisheng Pharmaceutical hitting the daily limit [9] - The high transmissibility of the flu virus has created a surge in demand for antiviral medications and related products [10] - Retail pharmacies are expected to benefit from increased demand for protective products such as masks and disinfectants [10]